Indica Labs and Lunit enters into alliance for digital pathology AI workflows

Indica Labs and Lunit enters into alliance for digital pathology AI workflows

Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution

  • By IPP Bureau | April 25, 2023

Indica Labs, an industry leader in quantitative digital pathology and image management innovations, and Lunit, a leading medical AI software platform company announced an agreement to provide a fully interoperable solution between Indica Labs’ HALO AP image management software platform and Lunit’s suite of AI pathology products. The combined solution is already in use at Guardant Health, a leading precision oncology company.

"Leveraging the power of digital pathology and artificial intelligence to improve tissue-based research and patient care is at the core of our mission," said Steven Hashagen, founder and CEO of Indica Labs. "This valued collaboration enables us to seamlessly integrate Lunit’s AI pathology solutions, including Lunit SCOPE PD-L1 for non-small cell lung cancer (NSCLC) into HALO AP, our CE-IVD certified clinical image management platform."

Brandon Suh, CEO of Lunit said, "The partnership with Indica Labs, a market leader in digital pathology, with interoperable workflow integration, will enable pathologists and labs to deliver faster, more accurate, and more reproducible answers using Lunit’s AI solutions."

Lunit SCOPE PD-L1 NSCLC is a CE-marked AI solution for detecting and analyzing PD-L1 TPS, a cancer biomarker. The solution may assist pathologists by minimizing interpretation variability and allowing better prediction of treatment outcomes for NSCLC patients, as demonstrated in study findings published in the European Journal of Cancer.

Indica Labs developed the HALO AP platform specifically to meet the needs of anatomic pathology labs worldwide.

Upcoming E-conference

Other Related stories